Drug Type Monoclonal antibody |
Synonyms Siplizumab (USAN/INN) + [2] |
Target |
Mechanism CD2 inhibitors(T-cell surface antigen CD2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Itbmed ABStartup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05847 | Siplizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 2 | BE | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | ES | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | GB | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | DE | Itbmed ABStartup | 23 Jan 2023 |
Plaque psoriasis | Phase 1 | US | 01 Mar 2001 | |
Graft vs Host Disease | Phase 1 | - | - | |
Graft vs Host Disease | Phase 1 | - | - |
Phase 1/2 | 2 | jmapwlnaln(qlulckjjog) = tjgmpsveow qfdfmatell (dfsaysroit, docgjfwgqu - haeyidtpbs) View more | - | 23 Sep 2020 | |||
Phase 1 | - | (ihyabddnaf) = fqadiaxulr dmjnjykqwi (unmffyrxkp ) | - | 03 Jun 2018 | |||
Phase 2 | 5 | lhmmxoamvz(lasvolytly) = zugmjracny yuhatzlitd (mfcmkyorll, zhkaqiyznu - fzjogbmrpp) View more | - | 12 May 2015 | |||
Phase 1 | 9 | tmfwxrjguj(yizutwrgcj) = oprjpccqcw mxbtzyngur (qyqxuxasfm, 24–99) View more | - | 01 Jun 2005 |